Evaluation of a person-centred, nurse-led model of care delivering hepatitis C testing and treatment in priority settings: a mixed-methods evaluation of the Tasmanian Eliminate Hepatitis C Australia Outreach Project, 2020–2022
-
Published:2023-11-20
Issue:1
Volume:23
Page:
-
ISSN:1471-2458
-
Container-title:BMC Public Health
-
language:en
-
Short-container-title:BMC Public Health
Author:
Dawe Joshua,Hughes Megan,Christensen Shannon,Walsh Louisa,Richmond Jacqueline A.,Pedrana Alisa,Wilkinson Anna L.,Owen Louise,Doyle Joseph S.,Hellard Margaret,Stoove Mark,Scott Nick,Howell Jess,Selvey Linda,Michaels Jessica,Crawford Sione,Fowlie Carrie,Singhal Shweta,Davies Jane,Manu Geoff,Ward James,Drenkhahn Geoff,Bastian Lisa,Dore Greg,Bryant Mellissa,Marshall Catherine,Llyod Andrew,McMahon Maria,Sattell Garry,Casey Dawn,Shaw David,Rees Tom,Thompson Alex,
Abstract
Abstract
Introduction
Australia has experienced sustained reductions in hepatitis C testing and treatment and may miss its 2030 elimination targets. Addressing gaps in community-based hepatitis C prescribing in priority settings that did not have, or did not prioritise, hepatitis C testing and treatment care pathways is critical.
Methods
The Tasmanian Eliminate Hepatitis C Australia Outreach Project delivered a nurse-led outreach model of care servicing hepatitis C priority populations in the community through the Tasmanian Statewide Sexual Health Service, supported by the Eliminating Hepatitis C Australia partnership. Settings included alcohol and other drug services, needle and syringe programs and mental health services. The project provided clients with clinical care across the hepatitis C cascade of care, including testing, treatment, and post-treatment support and hepatitis C education for staff.
Results
Between July 2020 and July 2022, a total of 43 sites were visited by one Clinical Nurse Consultant. There was a total of 695 interactions with clients across 219 days of service delivery by the Clinical Nurse Consultant. A total of 383 clients were tested for hepatitis C (antibody, RNA, or both). A total of 75 clients were diagnosed with hepatitis C RNA, of which 95% (71/75) commenced treatment, 83% (62/75) completed treatment and 52% (39/75) received a negative hepatitis C RNA test at least 12 weeks after treatment completion.
Conclusions
Providing outreach hepatitis C services in community-based services was effective in engaging people living with and at-risk of hepatitis C, in education, testing, and care. Nurse-led, person-centred care was critical to the success of the project. Our evaluation underscores the importance of employing a partnership approach when delivering hepatitis C models of care in community settings, and incorporating workforce education and capacity-building activities when working with non-specialist healthcare professionals.
Funder
Paul Ramsay Foundation
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health
Reference58 articles.
1. World Health Organization. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Geneva; 2021. 2. Trickey A, Fraser H, Lim AG, Peacock A, Colledge S, Walker JG, Leung J, Grebely J, Larney S, Martin NK, et al. The contribution of injection drug use to Hepatitis C virus transmission globally, regionally, and at country level: a modelling study. Lancet Gastroenterol Hepatol. 2019;4(6):435–44. 3. World Health Organization. Global hepatitis report, 2017. Geneva: World Health Organization; 2017. 4. Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med. 2017;166(9):637–48. 5. Hernandez-Con P, Wilson DL, Tang H, Unigwe I, Riaz M, Ourhaan N, Jiang X, Song HJ, Joseph A, Henry L, et al. Hepatitis C cascade of care in the direct-acting antivirals era: a meta-analysis. Am J Prev Med. 2023.
|
|